• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

40-O-(2-羟乙基)-雷帕霉素可减轻大鼠肺动脉高压和新生内膜形成。

40-O-(2-hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats.

作者信息

Nishimura T, Faul J L, Berry G J, Veve I, Pearl R G, Kao P N

机构信息

Division of Pulmonary and Critical Care Medicine, Department of Pathology, Stanford University Medical Center, Stanford, California 94305-5236, USA.

出版信息

Am J Respir Crit Care Med. 2001 Feb;163(2):498-502. doi: 10.1164/ajrccm.163.2.2006093.

DOI:10.1164/ajrccm.163.2.2006093
PMID:11179130
Abstract

Pneumonectomized rats develop pulmonary hypertension (PH) and pulmonary vascular neointimal formation 4 wk after monocrotaline (MCT) administration. Male Sprague-Dawley rats were injected with MCT (60 mg/kg) on Day 7 after left pneumonectomy. Three groups (n = 5) received 40-O-(2-hydroxyethyl)-rapamycin (RAD, 2.5 mg/kg/d, by gavage): Group PMR(5-35) from Day 5 to Day 35, Group PMR5-14 from Day 5 to Day 14, and Group PMR15-35 from Day 15 to Day 35. By Day 35, rats that received vehicle had higher mean pulmonary arterial pressures (Ppa = 41 +/- 3 mm Hg) (p < 0.001), right ventricular systolic pressures (Prv,s = 45 +/- 2 mm Hg) (p < 0.01), and right ventricle/(left ventricle plus septum) (0.55 +/- 0.05) (p = 0.028) than rats in Groups PMR5-35 (Ppa = 25 +/- 3 mm Hg, Prv,s = 32 +/- 7 mm Hg, RV/LV&S = 0.42 +/- 0.06) and PMR5-14 (Ppa = 29 +/- 4 mm Hg, Prv,s = 30 +/- 5 mm Hg, RV/LV&S = 0.43 +/- 0.07). Pulmonary arterial neointimal formation (quantified by a vascular occlusion score) was more severe in vehicle-treated rats (1.93 +/- 0.03) than in Groups PMR5-14 (1.56 +/- 0.27) and PMR(5-35) (1.57 +/- 0.1) (p < 0.01). RAD attenuates the development of MCT-induced pulmonary arterial hypertension in the pneumonectomized rat.

摘要

在给予野百合碱(MCT)4周后,肺切除大鼠会出现肺动脉高压(PH)和肺血管新内膜形成。雄性Sprague-Dawley大鼠在左肺切除术后第7天注射MCT(60mg/kg)。三组(n = 5)接受40-O-(2-羟乙基)-雷帕霉素(RAD,2.5mg/kg/d,经口灌胃):PMR(5 - 35)组从第5天至第35天,PMR5 - 14组从第5天至第14天,PMR15 - 35组从第15天至第35天。到第35天时,接受赋形剂的大鼠的平均肺动脉压(Ppa = 41±3mmHg)(p < 0.001)、右心室收缩压(Prv,s = 45±2mmHg)(p < 0.01)以及右心室/(左心室加室间隔)(0.55±0.05)(p = 0.028)均高于PMR5 - 35组(Ppa = 25±3mmHg,Prv,s = 32±7mmHg,RV/LV&S = 0.42±0.06)和PMR5 - 14组(Ppa = 29±4mmHg,Prv,s = 30±5mmHg,RV/LV&S = 0.43±0.07)的大鼠。在接受赋形剂治疗的大鼠中,肺动脉新内膜形成(通过血管闭塞评分量化)(1.93±0.03)比PMR5 - 14组(1.56±0.27)和PMR(5 - 35)组(1.57±0.1)更严重(p < 0.01)。RAD可减轻肺切除大鼠中MCT诱导的肺动脉高压的发展。

相似文献

1
40-O-(2-hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats.40-O-(2-羟乙基)-雷帕霉素可减轻大鼠肺动脉高压和新生内膜形成。
Am J Respir Crit Care Med. 2001 Feb;163(2):498-502. doi: 10.1164/ajrccm.163.2.2006093.
2
Triptolide attenuates pulmonary arterial hypertension and neointimal formation in rats.雷公藤甲素可减轻大鼠肺动脉高压和新生内膜形成。
Am J Respir Crit Care Med. 2000 Dec;162(6):2252-8. doi: 10.1164/ajrccm.162.6.2002018.
3
Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats.辛伐他汀可减轻大鼠平滑肌内膜增生和肺动脉高压。
Am J Respir Crit Care Med. 2002 Nov 15;166(10):1403-8. doi: 10.1164/rccm.200203-268OC. Epub 2002 Aug 15.
4
Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells.辛伐他汀通过诱导内膜平滑肌细胞凋亡,使大鼠免于致命性肺动脉高压。
Circulation. 2003 Sep 30;108(13):1640-5. doi: 10.1161/01.CIR.0000087592.47401.37. Epub 2003 Sep 8.
5
Diverse contribution of bone marrow-derived cells to vascular remodeling associated with pulmonary arterial hypertension and arterial neointimal formation.骨髓来源细胞对与肺动脉高压和动脉内膜形成相关的血管重塑的多种贡献。
Circulation. 2007 Jan 30;115(4):509-17. doi: 10.1161/CIRCULATIONAHA.106.655837. Epub 2007 Jan 22.
6
[Expression of GATA6 gene in lung tissue of rat with pulmonary hypertension].[GATA6基因在肺动脉高压大鼠肺组织中的表达]
Sichuan Da Xue Xue Bao Yi Xue Ban. 2006 Nov;37(6):864-7, 875.
7
Longitudinal transcriptional analysis of developing neointimal vascular occlusion and pulmonary hypertension in rats.大鼠新生内膜性血管闭塞和肺动脉高压发展过程的纵向转录分析
Physiol Genomics. 2004 Apr 13;17(2):150-6. doi: 10.1152/physiolgenomics.00198.2003.
8
[Effect of triptolide on the development of monocrotaline-induced pulmonary hypertension in pneumonectomized rat].
Sichuan Da Xue Xue Bao Yi Xue Ban. 2007 Sep;38(5):806-9.
9
[Effect of triptolide on the expression of matrix metalloproteinases 2 and 9 in lungs of experimental pulmonary hypertension].[雷公藤甲素对实验性肺动脉高压大鼠肺组织基质金属蛋白酶2和9表达的影响]
Zhongguo Dang Dai Er Ke Za Zhi. 2007 Oct;9(5):479-83.
10
Pulmonary hemodynamics modify the rat pulmonary artery response to injury. A neointimal model of pulmonary hypertension.肺血流动力学改变大鼠肺动脉对损伤的反应。肺动脉高压的新生内膜模型。
Am J Pathol. 1997 Oct;151(4):1019-25.

引用本文的文献

1
Searching for Old and New Small-Molecule Protein Kinase Inhibitors as Effective Treatments in Pulmonary Hypertension-A Systematic Review.寻找新旧小分子蛋白激酶抑制剂作为肺动脉高压的有效治疗方法——一项系统综述
Int J Mol Sci. 2024 Nov 29;25(23):12858. doi: 10.3390/ijms252312858.
2
[Pulmonary Vascular Remodeling Characteristics of Pulmonary Arterial Hypertension Mouse Model Induced by Left Pneumonectomy and Jugular Vein Injection of Monocrotaline Pyrrole].[左肺切除联合颈静脉注射野百合碱吡咯诱导的肺动脉高压小鼠模型的肺血管重塑特征]
Sichuan Da Xue Xue Bao Yi Xue Ban. 2022 Sep;53(5):821-827. doi: 10.12182/20220960508.
3
Senescence Alterations in Pulmonary Hypertension.
肺动脉高压中的衰老改变。
Cells. 2021 Dec 8;10(12):3456. doi: 10.3390/cells10123456.
4
Cytokines, Chemokines, and Inflammation in Pulmonary Arterial Hypertension.细胞因子、趋化因子与肺动脉高压中的炎症反应。
Adv Exp Med Biol. 2021;1303:275-303. doi: 10.1007/978-3-030-63046-1_15.
5
mTOR Signaling in Pulmonary Vascular Disease: Pathogenic Role and Therapeutic Target.mTOR 信号通路在肺血管疾病中的作用:致病机制及治疗靶点。
Int J Mol Sci. 2021 Feb 21;22(4):2144. doi: 10.3390/ijms22042144.
6
A 3-month, Multicenter, Randomized, Open-label Study to Evaluate the Impact on Wound Healing of the Early (vs Delayed) Introduction of Everolimus in De Novo Kidney Transplant Recipients, With a Follow-up Evaluation at 12 Months After Transplant (NEVERWOUND Study).一项为期 3 个月、多中心、随机、开放标签研究,旨在评估早期(与延迟)引入依维莫司对新诊断肾移植受者伤口愈合的影响,在移植后 12 个月进行随访评估(NEVERWOUND 研究)。
Transplantation. 2020 Feb;104(2):374-386. doi: 10.1097/TP.0000000000002851.
7
Repurposing Medications for Treatment of Pulmonary Arterial Hypertension: What's Old Is New Again.药物重新定位用于治疗肺动脉高压:旧药新用
J Am Heart Assoc. 2019 Jan 8;8(1):e011343. doi: 10.1161/JAHA.118.011343.
8
Pulmonary hypertension associated with neurofibromatosis type 1.与神经纤维瘤病 1 型相关的肺动脉高压。
Eur Respir Rev. 2018 Aug 29;27(149). doi: 10.1183/16000617.0053-2018. Print 2018 Sep 30.
9
Matrix metalloproteinases are possible targets in monocrotaline-induced pulmonary hypertension: investigation of anti-remodeling effects of alagebrium and everolimus.基质金属蛋白酶可能是野百合碱诱导的肺动脉高压的治疗靶点:对阿雷吉明和依维莫司抗重塑作用的研究
Anatol J Cardiol. 2017 Jan;17(1):8-17. doi: 10.14744/AnatolJCardiol.2016.6891. Epub 2016 Apr 26.
10
Ruscogenin exerts beneficial effects on monocrotaline-induced pulmonary hypertension by inhibiting NF-κB expression.鲁斯可皂苷元通过抑制核因子κB(NF-κB)的表达,对野百合碱诱导的肺动脉高压发挥有益作用。
Int J Clin Exp Pathol. 2015 Oct 1;8(10):12169-76. eCollection 2015.